Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

Published Date: 26 Apr 2023

The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.

Read Full News

Latest News

Common Anal Problems After Childbirth

Anal conditions affect up to 44% of women in labor yet remain underrecognized and poorly studied. Most cases improve with simple, conservative treatment.

China Approves CARsgen's CAR-T Treatment for Stomach Cancer

China's drug regulator said on Monday it has approved ⁠a CARsgen Therapeutics treatment for stomach cancer, a new milestone for CAR-T ⁠therapies, which engineer patients'...

Birth Factors Linked to Greater Early-Onset CRC Risk

Researchers conducted a population-based nested case-control study including individuals diagnosed with early-onset colorectal cancer and frequency-matched control individuals based on birth year.

Cholera Death Toll in Northeast Nigeria Rises to 90, UN Says

At least ⁠90 people have died and more than 12,000 ⁠others have been infected in a fast-spreading ⁠cholera outbreak in ‌Nigeria's conflict-hit Borno state, the U.N. Office...

Chronic Pain Conditions Burden Many With Rheumatic Diseases

Chronic overlapping pain conditions affect more than half of the adults with autoimmune rheumatic diseases, with distinct patterns seen across rheumatic disease subtypes.

Real-World Data Show Efficacy of Risankizumab in Crohn's

Risankizumab demonstrates effectiveness in achieving steroid-free clinical remission in the real-world cohort of patients with refractory Crohn's disease, with a favourable safety profile.

Todays Updates

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, ⁠citing unresolved issues found at a...

The New Perfectionism Problem in Medical Training

The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Todays Updates

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, ⁠citing unresolved issues found at a...

The New Perfectionism Problem in Medical Training

The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Latest News

Anal conditions affect up to 44% of women in labor yet remain underrecognized and poorly studied. Most cases improve with simple, conservative treatment.

China's drug regulator said on Monday it has approved ⁠a CARsgen Therapeutics treatment for stomach cancer, a new milestone for CAR-T ⁠therapies, which engineer patients'...

Researchers conducted a population-based nested case-control study including individuals diagnosed with early-onset colorectal cancer and frequency-matched control individuals based on birth year.

At least ⁠90 people have died and more than 12,000 ⁠others have been infected in a fast-spreading ⁠cholera outbreak in ‌Nigeria's conflict-hit Borno state, the U.N. Office...

Chronic overlapping pain conditions affect more than half of the adults with autoimmune rheumatic diseases, with distinct patterns seen across rheumatic disease subtypes.

Risankizumab demonstrates effectiveness in achieving steroid-free clinical remission in the real-world cohort of patients with refractory Crohn's disease, with a favourable safety profile.

News All Time

Iza-Bren Beats Chemo in Second-Line Esophageal Cancer

In a phase 3 trial, izalontamab brengitecan shows superiority to chemotherapy in previously treated esophageal squamous cell carcinoma, but questions remain about generalizability outside China.

Antibiotic Effects on the Gut Detected Up to 8 Years Later

Changes in gut microbiome diversity are observed with certain antibiotic drugs years later, even after just one course of therapy.

Natural Supplements Linked to Cases of Severe Liver Injury

Experts warn that concentrated herbal and dietary supplements are increasingly linked to severe liver injury, while regulation remains limited.

Remote Monitoring in Cirrhosis Could Reduce Admissions

A digital monitoring system for advanced cirrhosis may help detect deterioration earlier and reduce hospital admissions.

Blood Test Added to US Colorectal Cancer Screening Options

People who skip colorectal cancer screening because colonoscopy or stool testing seems too burdensome now have a blood test option from Guardant Health among recommendations...

Can Intraperitoneal Paclitaxel Improve OS in Gastric Cancer?

A phase 3 trial explores whether adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improves overall survival in patients with gastric cancer and peritoneal metastasis.

Pancreatic Cancer Testing Falls Short of Goals

Researchers conducted a cross-sectional electronic survey to see whether respondents were offered and completed germline genetic testing following a pancreatic ductal adenocarcinoma diagnosis.

Pancreatic Cysts: What’s the Actual Cancer Risk?

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

UTI Treatment Shift: Is Nitrofurantoin Coming Out on Top?

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

Takeda Engaged in Antitrust Scheme to Delay Generic Constipation Drug, US Jury Finds

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Housing Instability Tied to Lower Rates of CRC Screening

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

Blood Proteins Link Poor Sleep to Increased Cancer Risk

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Olanzapine Cuts Radiation-Induced Nausea

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

Barrett Esophagus Onset Occurs Decades Before Diagnosis

Molecular clock modeling suggests that the biological onset of Barrett esophagus occurs more than 20 years before the recommended screening age.

Silent Reflux: Clinical Conundrum Solved via Proper Testing

A chronic cough without heartburn are the tell-tale signs of the condition; surgery is typically not the answer.

Zenocutuzumab OK’d for NRG1 Fusion+ Cholangiocarcinoma

The bispecific antibody has previously granted accelerated approval for advanced, unresectable, or metastatic non-small cell lung cancer and pancreatic adenocarcinoma harboring the gene fusions.

Recommended News For You

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments

Regular physical activity before cancer diagnosis may lower progression and death risks

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Pickleball program boosts health and wellness for cancer survivors, study finds

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

Low PSA May Not Fully Predict Survival in Prostate Cancer

Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.

Recommended Articles For You

Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients 

Understanding Pomalidomide: A promising drug for multiple myeloma treatment 

Essential Concepts in Oncology for Better Care 

Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer

2.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

3.

Mezigdomide Combinations Show Promise in Multiple Myeloma

4.

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.

5.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

1.

Obesity is a major risk factor for cancer

2.

The Power of Salt Tablets: Unlocking Health Benefits Beyond Sodium

3.

Emerging Advances in Hematology and Quality Improvement

4.

LncRNAs in Cancer: Shaping Tumor Progression & Paving New Paths for Treatment

5.

Cardio-Oncology: Managing Heart Failure in Survivors of Cancer

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

2.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

3.

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

4.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot